<SEC-DOCUMENT>0001096906-25-001180.txt : 20250724
<SEC-HEADER>0001096906-25-001180.hdr.sgml : 20250724
<ACCEPTANCE-DATETIME>20250724140358
ACCESSION NUMBER:		0001096906-25-001180
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250724
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250724
DATE AS OF CHANGE:		20250724

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		251146282

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84070
		BUSINESS PHONE:		8015215301

	MAIL ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20250724.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fil="http://utahmed.com/20250724" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAAJHZFF]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="D250724" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="D250724" id="fact2">false</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="utmd-20250724.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<i:context id="D250724">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2025-07-24</i:startDate>
<i:endDate>2025-07-24</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:14pt Times New Roman;margin:0;text-align:center"><b>UNITED STATES </b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center"><b>Washington, D.C. &#160;20549</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center"><span style="font-size:14pt"><b>FORM </b><b><ix:nonNumeric name="dei:DocumentType" contextRef="D250724" escape="true" id="ixv-356">8-K</ix:nonNumeric></b></span></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>CURRENT REPORT</b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;text-align:center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">Date of Report (date of earliest event reported): <b><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="D250724" format="ixt:date-monthname-day-year-en" id="ixv-357">July 24, 2025</ix:nonNumeric></b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:14pt"><b><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="D250724" escape="true" id="ixv-358">UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="D250724" escape="true" id="ixv-359">UT</ix:nonNumeric></b><b>AH</b></span></p>
</td><td valign="top" style="width:2.6%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityFileNumber" contextRef="D250724" escape="true" id="ixv-360">000-12575</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="D250724" escape="true" id="ixv-361">87-0342734</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(State or other jurisdiction of</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Commission File Number)</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">(IRS Employer</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">incorporation or organization)</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">Identification No.)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="D250724" escape="true" id="ixv-362">7043 South 300 West</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="D250724" escape="true" id="ixv-363">Midvale</ix:nonNumeric></b><b>, </b><b><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="D250724" format="ixt-sec:stateprovnameen" id="ixv-364">Utah</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="D250724" escape="true" id="ixv-365">84047</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Address of principal executive offices)</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Zip code)</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:11pt Times New Roman;margin:0">Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b>Phone: </b><b>(</b><b><ix:nonNumeric name="dei:CityAreaCode" contextRef="D250724" escape="true" id="ixv-366">801</ix:nonNumeric></b><b>) </b><b><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="D250724" escape="true" id="ixv-367">566-1200</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:12pt Times New Roman;margin:0;text-align:center"><b>n/a</b></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="D250724" format="ixt-sec:boolballotbox" id="ixv-368">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="D250724" format="ixt-sec:boolballotbox" id="ixv-369">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="D250724" format="ixt-sec:boolballotbox" id="ixv-370">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="D250724" format="ixt-sec:boolballotbox" id="ixv-371">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="D250724" format="ixt-sec:boolballotbox" id="ixv-372">&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160;]</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:11pt Times New Roman;margin:0"><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:72pt;text-align:justify">Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and six months ended June 30, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated July 24, 2025. &#160;</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:72pt">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:72pt;text-align:justify">The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:90pt">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0"><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">The following is filed as an exhibit to this report: &#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Exhibit</b></p>
<p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Number*</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Title of Document</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Location</b></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:center"><b>Item 99.1</b></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify"><span style="font-size:12pt;color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex99z1.htm" style="text-decoration:none">Financial information for Utah Medical Prod</a><a href="utmd_ex99z1.htm" style="text-decoration:none">ucts, Inc. for the three and six months ended June 30, 2025</a><a href="utmd_ex99z1.htm" style="text-decoration:none"> and forward-loo</a><a href="utmd_ex99z1.htm" style="text-decoration:none">king statements relating to 2025</a><a href="utmd_ex99z1.htm" style="text-decoration:none"> and beyond as present</a><a href="utmd_ex99z1.htm" style="text-decoration:none">ed in a press release dated July 24, 2025</a><a href="utmd_ex99z1.htm" style="text-decoration:none">.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">This filing</p>
</td></tr>
</table>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">_______________________________________</p>
<p style="font:9pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:-18pt">*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center"><b>SIGNATURES</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify"><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">Dated:  July 24, 2025</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">By:</p>
</td><td valign="top" style="width:218.05pt;border-bottom:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0;text-align:justify">/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:218.05pt;border-top:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0;text-align:justify">Kevin L. Cornwell, Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND FORWARD-LOOKING STATEMENTS RELATING TO 2025 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED JULY 24, 2025.
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAAJHZFF]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><B>EXHIBIT 99.1</B></P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2025</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'>Contact: Brian Koopman (801) 566-1200</KBD><KBD style=margin-left:396pt></KBD>July 24, 2025&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Salt Lake City, Utah &#8211;&nbsp;Utah Medical Products, Inc. [Nasdaq: UTMD] reports second calendar quarter (2Q) and first half (1H) 2025 financial results which are consistent with overall beginning-of-year projections. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Overview of Results</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>In brief, consolidated total 2Q 2025 revenues were $447 (4.3%) lower than in 2Q 2024, with 1H 2025 revenues $2,077 (9.6%) lower than in 1H 2024. &nbsp;The lower sales in comparison with the prior year&#8217;s periods were dominated by a continued decline in sales to PendoTECH, representing 71% of the 2Q decline and 86% of the 1H decline. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s profit margins compared to those of the prior year&#8217;s same periods follow:</P>
<TABLE style=border-collapse:collapse;width:484.1pt;margin-left:-1.7pt><TR><TD valign=top style=width:232.1pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>2Q 2025 </P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'><FONT style='border-bottom:1px solid #000000'>(Apr &#8211;&nbsp;Jun)</FONT></P>
</TD><TD valign=top style='width:63.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>2Q 2024</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'><FONT style='border-bottom:1px solid #000000'>(Apr &#8211;&nbsp;Jun)</FONT></P>
</TD><TD valign=top style='width:63.75pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>1H 2025</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'><FONT style='border-bottom:1px solid #000000'>(Jan &#8211;&nbsp;Jun)</FONT></P>
</TD><TD valign=top style=width:60.65pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>1H 2024</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'><FONT style='border-bottom:1px solid #000000'>(Jan &#8211;&nbsp;Jun)</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:232.1pt><P style='font:11pt Times New Roman;margin:0'>Gross Profit Margin (GP/ sales):</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>56.2%</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:63.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>60.1% </P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:63.75pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>56.6%</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:60.65pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>59.9%</P>
</TD></TR>
<TR><TD valign=top style=width:232.1pt><P style='font:11pt Times New Roman;margin:0'>Operating Income Margin (OI/ sales):</P>
</TD><TD valign=top style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>32.1%</P>
</TD><TD valign=top style='width:63.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>33.1%</P>
</TD><TD valign=top style='width:63.75pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>32.3%</P>
</TD><TD valign=top style=width:60.65pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>33.7%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:232.1pt><P style='font:11pt Times New Roman;margin:0'>Income B4 Tax Margin (EBT/ sales):</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>38.5%</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:63.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>40.5%</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:63.75pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>39.1%</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:60.65pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>41.4%</P>
</TD></TR>
<TR><TD valign=top style=width:232.1pt><P style='font:11pt Times New Roman;margin:0'>Net Income Margin &nbsp;(NI/ sales)<I>:</I></P>
</TD><TD valign=top style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>30.6%</P>
</TD><TD valign=top style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>33.2%</P>
</TD><TD valign=top style=width:63.75pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>31.0%</P>
</TD><TD valign=top style=width:60.65pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>34.1%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The 2Q percentage decline in consolidated revenues was less than for 1H primarily because the period-to-period decline in UTMD sales to its previously major biopharmaceutical OEM customer PendoTECH decreased from $511 in 2Q 2024 to $196 in 2Q 2025, but from $2,056 in 1H 2024 to $264 in 1H 2025. Although the negative PendoTECH sales comparisons are bottoming out, looking forward to the rest of the year, UTMD expects 2H of 2025 PendoTECH sales will be about $200 lower than in 2H 2024. &nbsp;This would result in sales to this OEM customer for the 2025 year as a whole to be about $2 million lower compared to year 2024, which is consistent with projections provided at the beginning of 2025. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s Gross Profit (GP) margin contracted more than expected in 2Q 2025 primarily as a result of lower sales than expected and an unfavorable product mix for UTMD&#8217;s Ireland operations. Sales of devices from Utah operations maintained GP margins consistent with the prior 1Q 2025, as well as for year 2024. Operating Income (OI) declined less than the GP decline due to $355 lower 2Q 2025 U.S. litigation costs compared to 2Q 2024, and $791 lower litigation costs than in 1H 2024, which costs are included in Operating Expense per US GAAP, despite the negative impact of a weaker USD on Operating Expenses in Ireland and the UK.  Non-operating income resulting from 2025 interest rates lower than in 2024 caused the period-to-period EBT decline to be more than the OI decline. Although a higher estimated average income tax provision rate helped to increase the percentage period-to-period declines in Net Income (NI), share repurchases during 2Q 2025 and 1H 2025 helped to significantly mitigate the decline in EPS relative to NI. &nbsp;Please see the income statements on the last page of this report. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s June 30, 2025 Balance Sheet continued strong, with no debt. Ending Cash and Investments were $82.2 million compared to $83.0 million on December 31, 2024, after paying $2.0 million in cash </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>dividends to stockholders, repurchasing $6.7 million of UTMD common stock, increasing non-cash working capital by $0.3 million (including reducing current liabilities by $1.5 million) and investing $0.2 million in capital expenditures during 1H 2025. &nbsp;Please see the balance sheets on the last page of this report. </FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Revenues (sales)</FONT> -<FONT style='border-bottom:1px solid #000000'>2Q 2025 </FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 2Q 2025 UTMD worldwide (WW) sales in USD terms were $9,953 compared to $10,400 in 2Q 2024. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Consistent with the projection in UTMD&#8217;s SEC 10-K Report at the beginning of the year, sales of biopharma pressure monitoring devices and accessories to UTMD&#8217;s previously largest OEM customer, PendoTECH, were $315 (61.7%) lower in 2Q 2025 compared to 2Q 2024.  Sales to PendoTECH were $196 in 2Q 2025 compared to $511 in 2Q 2024.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Despite the lower 2Q 2025 sales to PendoTECH, which were all domestic, aggregated 2Q 2025 domestic sales were $5,865 compared to $5,831 in 2Q 2024. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic sales are invoiced in USD and obviously not subject to foreign currency conversion (FX) rate fluctuations. The components of domestic sales include 1) &#8220;direct non-Filshie device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;domestic Filshie device sales&#8221;. UTMD separates domestic Filshie device sales from other medical device sales direct to medical facilities because UTMD is simply a distributor for Femcare in the U.S. &nbsp;The domestic sales increase was because 2Q 2025 sales of the Filshie Clip System in the U.S. were $1,107 compared to $1,021, 8% higher than in 2Q 2024, and 2Q 2025 direct domestic sales of other devices were $4,047 compared to $3,670, 10% higher than in 2Q 2024. &nbsp;U.S. Filshie direct sales were 19% of total domestic sales compared to 18% in 2Q 2024. Direct non-Filshie device sales represented 69% of total domestic sales compared to 63% in 2Q 2024. &nbsp;In the remaining OEM domestic sales category, which includes PendoTECH, 2Q 2025 sales were $712 compared to $1,140 in 2Q 2024, 38% lower. &nbsp;Domestic OEM sales in 2Q 2025 were 12% of total domestic sales compared to 20% in 2Q 2024. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>On the other hand, 2Q 2025 international sales to customers outside the U.S. (OUS), were lower than expected. Total OUS sales in 2Q 2025 were $4,088 compared to $4,569 in 2Q 2024. In 2Q 2025, 37% of OUS sales were direct to medical facilities located in Ireland, the UK, France, Canada, Australia and New Zealand, compared to 39% in 2Q 2024. OUS direct to end-user sales are invoiced in foreign currencies. Despite the help from a weaker USD compared to the EUR and GBP in translating shipments invoiced in foreign currencies, 2Q 2025 OUS direct sales by UTMD&#8217;s Ireland, UK, Australia and Canada subsidiaries were just $1,503 compared to $1,785 in 2Q 2024. Canadian medical facilities openly put pressure on Canada distributors to not purchase medical devices from the U.S. In USD terms, including the impact of FX rate differences, total direct to end-user sales were $282 (15.8%) lower overall, including 21.5% lower in Ireland, 22.5% lower in Canada, 5.4% lower in the UK, 39.8% lower in Australia/New Zealand and 17.2% lower in France.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The remaining $2,585 in OUS sales in 2Q 2025, which were $200 lower than in 2Q 2024, were to distributors in other countries. These sales included export sales from the U.S. to OUS distributors invoiced in USD, and shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK invoiced in EUR and GBP. The timing of shipments to OUS distributors can cause significant fluctuations in quarterly comparisons since distributors tend to order larger quantities each time, in order to minimize transit and other logistical costs. The threat of reciprocal tariffs which have to be paid by distributors to their respective governments may have caused a pause for some. Although exports from Utah to OUS distributors invoiced in USD were $147 (+17.2%) higher, shipments from UTMD&#8217;s Ireland and the UK subsidiaries to OUS distributors were $347 (18%) lower. Shipments of blood pressure monitoring (BPM) kits from Ireland to UTMD&#8217;s largest BPM medical device distributor </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>located in China were $93 higher, but Ireland shipments to OUS distributors of other devices were $441 lower. </FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The portion of OUS sales invoiced in foreign currencies in USD terms were 31% of total WW consolidated 2Q 2025 sales compared to 35% in 2Q 2024. The average USD FX rates increased 2Q 2025 total consolidated sales $173 for sales invoiced in foreign currencies. <A name=_Hlk108176647 />Actually, a stronger GBP and EUR together added $180. The CAD and AUD were weaker. &nbsp;FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 2Q 2025 and 2Q 2024 for revenue purposes follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR style=height:7.2pt><TD valign=top style=width:13.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:39.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:22.95pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:63pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2025</FONT></P>
</TD><TD valign=top style=width:67.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2024</FONT></P>
</TD><TD valign=top style=width:58.65pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:13.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:39.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:22.95pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:63pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.3368</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.2615</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.65pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;+6.0%</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:13.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:39.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:22.95pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:63pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.1569</P>
</TD><TD valign=top style=width:67.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.0752</P>
</TD><TD valign=top style=width:58.65pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;+7.6%</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:13.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:39.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:22.95pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:63pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.6394</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.6594</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.65pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;( 3.0%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:13.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:39.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:22.95pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:63pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.7227</P>
</TD><TD valign=top style=width:67.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.7308</P>
</TD><TD valign=top style=width:58.65pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;( 1.1%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The $173 weighted average favorable impact on 2Q 2025 foreign currency OUS sales was 6.0%. &nbsp;In constant currency terms, foreign currency sales in 2Q 2025 were 21.4% lower than in 2Q 2024. &#8220;Constant currency&#8221; sales means exchanging foreign currency sales into USD-denominated sales at the same FX rate as was in the previous period of time being compared.  &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Sales</FONT> -<FONT style='border-bottom:1px solid #000000'>1H 2025 </FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 1H 2025 UTMD worldwide (WW) sales in USD terms were $19,663 compared to $21,740 in 1H 2024. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Consistent with the projection in UTMD&#8217;s SEC 10-K Report at the beginning of the year, sales of biopharma pressure monitoring devices and accessories to UTMD&#8217;s previously largest OEM customer, PendoTECH, were $1,791 (87.1%) lower in 1H 2025 compared to 1H 2024.  WW sales to PendoTECH were $265 in 1H 2025 (all in the U.S.) compared to $2,056 in 1H 2024 ($1,627 in the U.S. and $429 in Ireland).</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Aggregated 1H 2025 domestic sales at $11,448 compared to $12,022 in 1H 2024 were $574 lower, despite the 1H $1,362 lower 2025 domestic sales to PendoTECH. &nbsp;In other words, 1H 2025 domestic sales excluding PendoTECH were $11,184 compared to $10,396 in 1H 2024, 7.6% higher.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic sales are invoiced in USD and obviously not subject to foreign currency conversion (FX) rate fluctuations. The components of domestic sales include 1) &#8220;direct non-Filshie device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;domestic Filshie device sales&#8221;. UTMD separates domestic Filshie device sales from other medical device sales direct to medical facilities because UTMD is simply a distributor for Femcare in the U.S. &nbsp;The non-PendoTECH domestic sales increase was because 1H 2025 sales of the Filshie Clip System in the U.S. were $2,146 compared to $2,082, 3% higher than in 1H 2024, and 1H 2025 direct domestic sales of other devices were $7,962 compared to $7,180, 11% higher than in 1H 2024. &nbsp;U.S. Filshie direct sales were 19% of total 1H 2025 domestic sales compared to 17% in 1H 2024. Direct non-Filshie device sales represented 70% of total domestic sales compared to 60% in 1H 2024. &nbsp;In the remaining OEM domestic sales category, which includes PendoTECH, 1H 2025 sales were $1,340 compared to $2,760 in 1H 2024, 51% lower. &nbsp;Domestic OEM sales in 1H 2025 were 12% of total domestic sales compared to 23% in 1H 2024. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>On the other hand, 1H 2025 international sales to customers outside the U.S. (OUS), were lower than expected. Total OUS sales in 1H 2025 were 15.5% lower at $8,215 compared to $9,718 in 1H 2024. Excluding PendoTECH OUS sales which were in 1Q, 1H 2024 sales were $9,289. &nbsp;So, OUS sales excluding PendoTECH in 1H 2025 were 11.6% lower than in 1H 2024. &nbsp;In both 1H 2025 and 1H 2024, </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>37% of OUS sales were direct to medical facilities located in Ireland, the UK, France, Canada, Australia and New Zealand. OUS direct to end-user sales are invoiced in foreign currencies. Despite the help from a weaker USD compared to the EUR and GBP in translating shipments invoiced in foreign currencies, 1H 2025 OUS direct sales by UTMD&#8217;s Ireland, UK, Australia and Canada subsidiaries were $3,079 compared to $3,609 in 1H 2024. In USD terms, including the impact of FX rate differences, total direct to end-user sales were $530 (14.7%) lower overall, including 27.4% lower in Ireland, 22.1% lower in Canada, 6.6% lower in the UK, 20.6% lower in Australia/New Zealand and 21.4% lower in France.</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The remaining $5,136 in OUS sales in 1H 2025, which were $973 lower than in 1H 2024, were to distributors in other countries. These sales included export sales from the U.S. to OUS distributors invoiced in USD, and shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK invoiced in EUR and GBP. The timing of shipments to OUS distributors can cause significant fluctuations in quarterly comparisons since distributors tend to order larger quantities each time, in order to minimize transit and other logistical costs. Exports from Utah to OUS distributors invoiced in USD were $69 (3.3%) lower. &nbsp;Shipments from UTMD&#8217;s Ireland and the UK subsidiaries to OUS distributors were $904 (22.4%) lower. Shipments of blood pressure monitoring (BPM) kits from Ireland to UTMD&#8217;s largest BPM medical device distributor located in China were $71 higher, but Ireland shipments to OUS distributors of other devices were $964 lower. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The portion of OUS sales invoiced in foreign currencies in USD terms were 31% of total WW consolidated 1H 2025 sales compared to 33% in 1H 2024. The average USD FX rates increased 1H 2025 total consolidated sales $130 for sales invoiced in foreign currencies. Actually, a stronger GBP and EUR together added $160. The CAD and AUD were weaker. &nbsp;FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1H 2025 and 1H 2024 for revenue purposes follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR style=height:4.25pt><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:43.2pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:14pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>1H<BR><FONT style='border-bottom:1px solid #000000'>2025</FONT></P>
</TD><TD valign=bottom style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>1H<BR><FONT style='border-bottom:1px solid #000000'>2024</FONT></P>
</TD><TD valign=bottom style=width:54.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR style=height:4.25pt><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:43.2pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:14pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.2977</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.2646</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:54.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;+2.6%</P>
</TD></TR>
<TR style=height:4.25pt><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:43.2pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:14pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.1155</P>
</TD><TD valign=top style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.0787</P>
</TD><TD valign=top style=width:54.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;+3.4%</P>
</TD></TR>
<TR style=height:4.25pt><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:43.2pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:14pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.6329</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.6586</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:54.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;( 3.9%)</P>
</TD></TR>
<TR style=height:4.25pt><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:43.2pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:14pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.7094</P>
</TD><TD valign=top style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.7362</P>
</TD><TD valign=top style=width:54.7pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;( 3.6%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The $130 weighted average favorable impact on 1H 2025 foreign currency OUS sales was 2.2%. &nbsp;In constant currency terms, foreign currency sales in 1H 2025 were 18.0% lower than in 1H 2024. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>GP results from subtracting the cost of goods sold (CGS), comprised of costs of production, manufacturing engineering, depreciation of equipment, maintenance and repairs, quality assurance including regulatory compliance, and purchasing including freight for receiving materials from suppliers, from revenues. CGS is divided into three categories: direct labor, raw materials and manufacturing overhead (MOH). &nbsp;Direct labor and raw materials are predominantly variable costs, i.e. vary directly with revenues. &nbsp;MOH contains many fixed costs consistent with the Company&#8217;s infrastructure, for example, supervision and engineering personnel.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s 2Q 2025 GP was $658 (10.5%) lower than in 2Q 2024. GP in 1H 2025 was $1,885 (14.5%) lower than in 1H 2024. The consolidated 2Q 2025 GP margin was 56.2% compared to 60.1% in 2Q 2024. &nbsp;The 1H 2025 GPM was 56.6% compared to 59.9% in 1H 2024. &nbsp; &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The lower margins were primarily due to Ireland operations, as a result of an unfavorable product mix, &nbsp;lower sales which absorbed less fixed manufacturing overhead costs, higher raw material costs and an increase in intercompany finished goods inventory manufactured in Ireland which required reserved gross profit. With absorption of MOH helped by higher direct sales, gross margins in the U.S. were consistent with past periods in 2024, and in 1Q 2025. &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>OI results from subtracting Operating Expenses (OE) from GP. &nbsp;OE are comprised of Sales and Marketing (S&amp;M) expenses, General and Administrative (G&amp;A) expenses and Product Development (R&amp;D) expenses. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OI in 2Q 2025 of $3,196 was $242 (7.1%) lower compared to 2Q 2024 OI of $3,438. &nbsp;<A name=_Hlk172206782 />The lower OI <A name=_Hlk140777717 />was the result of $658 lower GP offset by $416 lower OE, explained below. UTMD&#8217;s 2Q 2025 OI Margin (OI as a percentage of sales) remained a healthy 32.1%. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OI in 1H 2025 was $6,349 compared to $7,321 in 1H 2024, a decrease of $972 (13.3%), with a continuing healthy 1H 2025 OI margin of 32.3%. &nbsp;The lower OI was the result of $1,885 lower GP offset by $913 lower OE, explained below.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The following table summarizes OE in 2Q and 1H 2025 compared to the same periods in 2024 by OE category:</P>
<TABLE style=border-collapse:collapse><TR><TD valign=bottom style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>OE</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2025</FONT></P>
</TD><TD valign=bottom style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2024</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2025</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2024</FONT></P>
</TD><TD valign=bottom style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>$ 524</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;5.3</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 546</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;5.3</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'> $1,024 </P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;5.2</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 958</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;4.4</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>1,740</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>17.5</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,014</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.4</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>3,470</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>17.6</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>4,219</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>19.4</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style='width:59.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>R&amp;D:</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:54pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;135</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:43.8pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;1.3</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;255</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-bottom:0.5pt solid #000000;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2.4</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-left:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;290</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;1.5</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;520</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2.4</P>
</TD></TR>
<TR><TD valign=top style='width:59.4pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=top style='width:54pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,399</P>
</TD><TD valign=top style='width:43.8pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>24.1</P>
</TD><TD valign=top style='width:52.4pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,815</P>
</TD><TD valign=top style='width:52.4pt;border-top:0.5pt solid #000000;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>27.1</P>
</TD><TD valign=top style='width:52.4pt;border-top:0.5pt solid #000000;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>4,784</P>
</TD><TD valign=top style='width:52.4pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>24.3</P>
</TD><TD valign=top style='width:52.4pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>5,697</P>
</TD><TD valign=top style='width:52.4pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>26.2</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Because of lower S&amp;M expenses in 2Q 2025 along with lower sales, S&amp;M expenses as a percentage of sales remained the same. &nbsp;In 1H 2025, higher expenses with lower sales increased S&amp;M expenses as a percentage of sales to 5.2% from 4.4% in 1H 2024.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>S&amp;M OE were $22 lower in 2Q 2025 and $66 higher in 1H 2025 compared to the same periods in 2024 respectively. UTMD in the U.S. is self-insured for its employee health plan. The lower S&amp;M expenses in 2Q 2025 compared to 2Q 2024 can be explained primarily by a lower medical expense accrual. About two-thirds of the higher 1H S&amp;M expenses were in the U.S., with increases spread about evenly among several categories: salaries and consulting fees, trade show expenses, fees paid to national distributors and lower recovered freight costs reimbursed by customers. The remaining third of the higher 1H 2025 expenses was about evenly split between Ireland and Australia: &nbsp;salaries in Australia and recovered freight costs in Ireland. The impact of differences in FX rates on foreign subsidiary S&amp;M expenses added $4 in 2Q 2025 and $2 in 1H 2025 (see below). &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>G&amp;A expenses dominate UTMD&#8217;s OE, largely because of non-cash expenses from the amortization of Identifiable Intangible Assets (IIA) associated with the Filshie Clip System and the expenses of current litigation in the U.S. &nbsp;A segmentation of USD-denominated G&amp;A expenses follows:  </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:464.2pt><TR style=height:25.3pt><TD valign=top style=width:91.75pt><P style='font:11pt Times New Roman;margin:0'>G&amp;A Exp<BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:57.45pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2025</FONT></P>
</TD><TD valign=bottom style='width:38.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:55.7pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2024</FONT></P>
</TD><TD valign=bottom style='width:35.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:55.85pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2025</FONT></P>
</TD><TD valign=bottom style='width:38.1pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:55.85pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2024</FONT></P>
</TD><TD valign=bottom style=width:35.5pt><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR style=height:12.65pt><TD valign=top bgcolor=#D3F0FE style=width:91.75pt><P style='font:11pt Times New Roman;margin:0'>IIA Amort- UK:</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:57.45pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 531</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:38.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> 5.3</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:55.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$ 501</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:35.5pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> 4.8</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:55.85pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$1,032</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:38.1pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;5.2</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:55.85pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$1,005</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:35.5pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;4.6</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style=width:91.75pt><P style='font:11pt Times New Roman;margin:0'>Other &#8211; UK:</P>
</TD><TD valign=top style=width:57.45pt><P align=right style='font:11pt Times New Roman;margin:0'>189</P>
</TD><TD valign=top style='width:38.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:55.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>173</P>
</TD><TD valign=top style='width:35.5pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:55.85pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>379</P>
</TD><TD valign=top style='width:38.1pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:55.85pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>360</P>
</TD><TD valign=top style=width:35.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:12.65pt><TD valign=top bgcolor=#D3F0FE style=width:91.75pt><P style='font:11pt Times New Roman;margin:0'>U.S. Litigation</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:57.45pt><P align=right style='font:11pt Times New Roman;margin:0'>280</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:38.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>2.8</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:55.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>635</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:35.5pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>6.1</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:55.85pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>587</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:38.1pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>3.0</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:55.85pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,378</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:35.5pt><P align=right style='font:11pt Times New Roman;margin:0'>6.3</P>
</TD></TR>
<TR style=height:12.65pt><TD valign=top style=width:91.75pt><P style='font:11pt Times New Roman;margin:0'>Other &#8211;&nbsp;US</P>
</TD><TD valign=top style=width:57.45pt><P align=right style='font:11pt Times New Roman;margin:0'>603</P>
</TD><TD valign=top style='width:38.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>6.1</P>
</TD><TD valign=top style='width:55.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>557</P>
</TD><TD valign=top style='width:35.5pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>5.4</P>
</TD><TD valign=top style='width:55.85pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,197</P>
</TD><TD valign=top style='width:38.1pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>6.1</P>
</TD><TD valign=top style='width:55.85pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,158</P>
</TD><TD valign=top style=width:35.5pt><P align=right style='font:11pt Times New Roman;margin:0'>5.3</P>
</TD></TR>
<TR style=height:12.65pt><TD valign=top bgcolor=#D3F0FE style=width:91.75pt><P style='font:11pt Times New Roman;margin:0'>IRE:</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:57.45pt><P align=right style='font:11pt Times New Roman;margin:0'>88</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:38.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:55.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>92</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:35.5pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:55.85pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>172</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:38.1pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:55.85pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>186</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:35.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:12.65pt><TD valign=top style=width:91.75pt><P style='font:11pt Times New Roman;margin:0'>AUS:</P>
</TD><TD valign=top style=width:57.45pt><P align=right style='font:11pt Times New Roman;margin:0'>16</P>
</TD><TD valign=top style='width:38.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:55.7pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>24</P>
</TD><TD valign=top style='width:35.5pt;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:55.85pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>34</P>
</TD><TD valign=top style='width:38.1pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:55.85pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>66</P>
</TD><TD valign=top style=width:35.5pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:12.65pt><TD valign=top bgcolor=#D3F0FE style='width:91.75pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>CAN:</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:57.45pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>33</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:38.5pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:55.7pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>32</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:35.5pt;border-bottom:0.5pt solid #000000;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:55.85pt;border-left:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>69</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:38.1pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:55.85pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>66</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:35.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:11.9pt><TD valign=top style='width:91.75pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Total G&amp;A:</P>
</TD><TD valign=top style='width:57.45pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,740</P>
</TD><TD valign=top style='width:38.5pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>17.5</P>
</TD><TD valign=top style='width:55.7pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>2,014</P>
</TD><TD valign=top style='width:35.5pt;border-top:0.5pt solid #000000;border-right:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>19.4</P>
</TD><TD valign=top style='width:55.85pt;border-top:0.5pt solid #000000;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>3,470</P>
</TD><TD valign=top style='width:38.1pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>17.6</P>
</TD><TD valign=top style='width:55.85pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>4,219</P>
</TD><TD valign=top style='width:35.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>19.4</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>Total consolidated G&amp;A expenses in 2Q 2025 were $274 lower, and in 1H 2025 were $749 lower than in the same periods in 2024. &nbsp;The primary cause was lower U.S. litigation expenses - $355 lower in 2Q 2025 compared to 2Q 2024, and $791 lower in 1H 2025 compared to 1H 2024. &nbsp;Offsetting the significant G&amp;A expense reduction from lower litigation expenses, foreign currency G&amp;A expenses expressed in USD were increased by FX rate differences by $46 in 2Q 2025 and $38 in 1H 2025. &nbsp;In 2Q 2025, $30 of the $46 higher expense FX impact was the non-cash identifiable intangible asset (IIA) amortization&#8211;UK expense which resulted from the 2011 acquisition of Femcare. The IIA amortization expense in GBP was the same in both periods. Similarly, in 1H 2025, $27 of the $38 higher expense FX impact was the non-cash identifiable intangible asset (IIA) amortization&#8211;UK. As a side note, the Femcare IIA non-cash amortization expense, which has reduced OI approximately $2 million per year since 2011, will be fully amortized in 1Q 2026. Other-US G&amp;A expenses were $46 higher in 2Q 2025 compared to 2Q 2024, and $39 higher in 1H 2025 compared to 1H 2024. The 2Q 2025 $46 increase was due to $34 higher non-cash stock option expense along with increased independent financial auditor fees and other outside services. &nbsp;The 1H 2025 $39 net higher Other-US G&amp;A expenses were essentially due to $37 higher stock option expense, $24 higher accounting and other outside services, and $12 higher outside director fees offset by $32 lower salaries. &nbsp;Other G&amp;A expenses in the aggregate were similar in both periods. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The differences in period-to-period R&amp;D expenses were primarily due to the completion of independent validation of material composition of biopharma sensors. Since all R&amp;D in 2025 was carried out in the U.S., there was no FX rate impact. &nbsp; </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The impact of differing FX rates in 2025 and 2024 on OE expressed in USD was minor. The AUD and CAD were slightly weaker, but the EUR and GBP stronger which helped increase foreign currency OE when converted to USD by a net $50 in 2Q 2025 and $40 in 1H 2025. The following table summarizes &#8220;constant currency&#8221; OE in 2Q and 1H 2025 compared to the same periods in 2024 by OE category:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:59.25pt><P style='font:11pt Times New Roman;margin:0'>OE<BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:53.7pt><P align=center style='font:11pt Times New Roman;margin:0'>2Q 2025 <FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style='width:13.05pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:58.5pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2024</FONT></P>
</TD><TD valign=bottom style='width:18pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:63pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1H 2025 <FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style='width:13.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:67.5pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2024</FONT></P>
</TD><TD valign=bottom style=width:121.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:59.25pt><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:53.7pt><P align=center style='font:11pt Times New Roman;margin:0'>$ 520</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:13.05pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 546</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:18pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:63pt;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'> $1,022</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:13.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:67.5pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 958</P>
</TD><TD valign=top style=width:121.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.25pt><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:53.7pt><P align=center style='font:11pt Times New Roman;margin:0'>1,694</P>
</TD><TD valign=top style='width:13.05pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,014</P>
</TD><TD valign=top style='width:18pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:63pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>3,432</P>
</TD><TD valign=top style='width:13.5pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:67.5pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>4,219</P>
</TD><TD valign=top style=width:121.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style='width:59.25pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>R&amp;D:</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:53.7pt;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;135</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:13.05pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;255</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:18pt;border-bottom:0.5pt solid #000000;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:63pt;border-left:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;290</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:13.5pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:67.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;520</P>
</TD><TD valign=top style=width:121.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:59.25pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=top style='width:53.7pt;border-top:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,349</P>
</TD><TD valign=top style='width:13.05pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,815</P>
</TD><TD valign=top style='width:18pt;border-top:0.5pt solid #000000;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:63pt;border-top:0.5pt solid #000000;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>4,744</P>
</TD><TD valign=top style='width:13.5pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:67.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>5,697</P>
</TD><TD valign=top style=width:121.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. &nbsp;Consolidated 2Q 2025 EBT was $3,835 (38.5% of sales) compared to $4,211 (40.5% of sales) in 2Q 2024. Consolidated 1H 2025 EBT was $7,694 (39.1% of sales) compared to $9,010 (41.4% of sales) in 1H 2024.  &nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms on June 30, 2025; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company&#8217;s technology. Starting in 2024 for UTMD, there is an additional excise tax included in NOE: a stock repurchase excise tax included in the so-called &#8220;Inflation Reduction Act of 2022&#8221;. &nbsp;After the U.S. Treasury and IRS announced regulations governing the stock repurchase excise tax in 2Q 2024, UTMD began reporting the NOE in its 2Q 2024 income statement for the $9,393 in share repurchases made during 1H 2024. &nbsp;Shares repurchased in 2Q 2025 and 1H 2025 were $3,488 and $6,709 respectively. Due to the new tax, UTMD incurred a pretax decrease in stockholder value of $67 in 1H 2025 and $94 in 1H 2024. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Net NOI is NOI minus NOE. &nbsp;Net NOI in 2Q 2025 was $640 compared to $773 net NOI in 2Q 2024. Net NOI in 1H 2025 was $1,345 compared to $1,688 in 1H 2024. With lower cash balances due to share repurchases in 2025, and lower interest rates, UTMD received approximately $332 less in 1H 2025 </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>interest income compared to 1H 2024.  Remeasured foreign currency balances generated about $7 more in net NOI in 1H 2025 compared to 1H 2024. &nbsp;  &nbsp;</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial operating performance, as well as its ability to sustain high level financial performance during a challenging time. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 2Q 2025 consolidated EBT excluding the remeasured bank balance currency gain or loss (&#8220;adjusted consolidated EBITDA&#8221;) was $4,671 (46.9% of sales) compared to $4,942 (47.5% of sales) in 2Q 2024. Adjusted consolidated EBITDA was $9,323 (47.4% of sales) in 1H 2025 compared to $10,489 (48.3% of sales) in 1H 2024. The lower EBITDA in both 2Q and 1H 2025 was due to lower GP. Adjusted consolidated trailing twelve months&#8217; (TTM) EBITDA was $18,686 as of June 30, 2025. Management&#8217;s beginning of year EBITDA target of $17-$18 million continues to look achievable. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number: &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:432pt;margin-left:5.4pt><TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2025</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2024</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2025</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2024</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:207pt><P style='font:11pt Times New Roman;margin:0'>EBT</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 3,835</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$ 4,211</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$7,694</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'> $9,010</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Depreciation Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>206</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>172</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>405</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>327</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Femcare IIA Amortization Expense</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>531</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>501</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,032</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>1,005</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:49.5pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.5pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Other Non-Cash Amortization Expense</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>8</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>8</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>17</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>18</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Stock Option Compensation Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>86 </P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>52</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>168</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>130</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Interest Expense</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top style='width:207pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Remeasured Foreign Currency Balances</P>
</TD><TD valign=top style='width:49.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>(2)</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>7</P>
</TD><TD valign=top style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>(1)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style='width:207pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>UTMD non-US GAAP EBITDA:</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:49.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$4,671</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$4,942</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$9,323</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$10,489</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'><A name=_Hlk140828510 />NI in 2Q 2025 of $3,048 (30.6% of sales) was 11.7% lower than the NI of $3,453 (33.2% of sales) in 2Q 2024. &nbsp;<A name=_Hlk172296323 />The $405 lower 2Q NI was due to $243 lower OI combined with $133 lower net NOI, and a higher estimated average income tax provision rate. The average consolidated income tax provision rate (as a % of the same period EBT) in 2Q 2025 was 20.5% compared to 18.0% in 2Q 2024.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>NI in 1H 2025 of $6,089 (31.0% of sales) was 17.8% lower than the NI of $7,409 (34.1% of sales) in 1H 2024. &nbsp;The $1,320 lower 1H 2025 NI was due to $972 lower OI combined with $343 lower net NOI, and a higher estimated average income tax provision rate. The average consolidated income tax provision rate (as a % of the same period EBT) in 1H 2025 was 20.9% compared to 17.8% in 1H 2024.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. The basic corporate income tax rates in each of the sovereignties were the same as in the prior year. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Diluted EPS in 2Q 2025 were $0.939 compared to diluted EPS of $0.978 in 2Q 2024, a 4.0% decrease. Diluted EPS in 1H 2025 were $1.858 compared to diluted EPS of $2.070 in 1H 2024, a 10.3% decrease. The percentage decreases in EPS were substantially lower than the decreases in NI as a result of fewer diluted shares. &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>Diluted shares were 3,245,979 in 2Q 2025 compared to 3,531,572 in 2Q 2024. &nbsp;Diluted shares were 3,277,936 in 1H 2025 compared to 3,579,435 in 1H 2024. The lower diluted shares in both periods of 2025 were the result of shares repurchased during 1H 2025. Because the average exercise price of employee options was higher than the ending market price of the stock in both 2Q 2025 and 2Q 2024, the number of shares added as a dilution factor in both 2Q 2025 and 2Q 2024 were zero. The same was true for both 1H 2025 and 1H 2024. The number of shares used for calculating EPS in both years was higher than period-ending outstanding shares because of a time-weighted calculation of average outstanding shares. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Outstanding shares at the end of 2Q 2025 were 3,215,901 compared to 3,335,156 at the end of calendar year 2024. The difference was due to 119,255 shares repurchased in 1H 2025. Shares repurchased in 2Q 2025 were 64,988 at an average price of $53.67. &nbsp;Shares repurchased in 1H 2025 were 119,255, at an average price of $56.26. &nbsp;The total cost of repurchasing shares in 1H 2025 was $6,709 plus a 1% excise tax. Outstanding shares one year earlier were 3,498,902 at the end of 2Q 2024. Outstanding shares at the end of calendar 2023 were 3,629,525. The total cost of repurchasing 421,216 shares in the six calendar quarters since the end of 2023 was $26,676 plus a 1% federal excise tax. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The total number of outstanding unexercised employee and outside director options at June 30, 2025 was 97,685 at an average exercise price of $73.76, including shares awarded but not yet vested. &nbsp;This compares to 73,497 unexercised option shares at the end of 2Q 2024 at an average exercise price of $77.01/ share, including shares awarded but not vested. No employee options have been awarded in 2025. &nbsp;Non-qualified option awards totaling 24,600 shares were made to 47 employees and one director in November 2024 at an exercise price of $64.09. &nbsp; </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD paid $1,001 ($0.305/share) in dividends to stockholders in 2Q 2025 compared to $1,081 ($0.300/ share) paid in 2Q 2024. <A name=_Hlk140832217 />The dividends paid to stockholders during 2Q 2025 were 33% of NI. UTMD paid $2,018 ($0.305/share) in dividends to stockholders in 1H 2025 compared to $2,170 ($0.300/ share) paid in 1H 2024. The dividends paid to stockholders during 1H 2025 were 33% of NI.  </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s closing share price at the end of 2Q 2025 was $56.92 up 1.6% from the closing price of $56.04 at the end of 1Q 2025, and down 7.4% from the closing price of $61.47 at the end of 2024. &nbsp;The closing share price one year ago at the end of 2Q 2024 was $66.81. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>At June 30, 2025 compared to the end of 2024, UTMD&#8217;s cash and investments balance declined only $797 to $82,179 despite use of $6,708 cash for share repurchases, $2,018 cash for dividends to stockholders, and $235 cash for capital equipment purchases. At June 30, 2025, net Intangible Assets decreased to 13.4% of total consolidated assets from 13.5% on June 30, 2024 despite a weaker USD which increased GBP-valued intangible assets 8.6%. UTMD&#8217;s very strong 41.9 current ratio at June 30, 2025 was higher than the 25.6 current ratio at December 31, 2024 as a result of favorable 1H 2025 non-cash working capital changes exceeding the negative impact of slightly reducing cash. The average age of trade receivables was 33 days from date of invoice at June 30, 2025 compared to 40 days at December 31, 2024, based on the most recent calendar quarter of sales. Average inventory turns improved to 2.1 in 2Q 2025 compared to 2.0 for the last quarter of 2024, as inventory balances declined $579. Ending 2Q 2025 accrued liabilities declined $845 from the ending of 2024.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 2Q 2025 compared to the end of calendar year 2024 and the end of 2Q 2024 were</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>6-30-25</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>12-31-24</FONT></P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>6-30-24</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>1.37213</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>1.25209</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;9.6%</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1.26371</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;8.6%</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>1.17706</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>1.03505</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> 13.7%</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1.07109</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;9.9%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>0.65722</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>0.61834</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;6.3%</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.66742</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;(1.5%)</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>0.73422</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>0.69428</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;5.8%</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.73068</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;0.5%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Financial ratios as of June 30, 2025 which may be of interest to stockholders follow:</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 41.9&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 2Q 2025 sales activity) = 33&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns (based on 2Q 2025 CGS) = 2.1&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>4)</KBD>2025 YTD ROE (before dividends) = 10%&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare and the economy in general such as tariffs, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style=color:#215E99><B>www.utahmed.com</B>.</FONT></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-size:13pt><B>Utah Medical Products, Inc.</B></FONT></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, Second Quarter (three months ended June 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share):</P>
<TABLE style=border-collapse:collapse;width:512.7pt><TR style=height:7.2pt><TD valign=top style=width:140.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2025</FONT></P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2024</FONT></P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:140.4pt><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 9,953</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 10,400</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:78.15pt><P align=center style='font:10pt Times New Roman;margin:0'>( &nbsp;4.3%)</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style='width:140.4pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style='width:67.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>5,595</P>
</TD><TD valign=top style='width:70.35pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>6,253</P>
</TD><TD valign=top style='width:78.15pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(10.5%)</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style='width:140.4pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:67.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,196</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:70.35pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,438</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:78.15pt;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>( &nbsp;7.1%)</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style='width:140.4pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style='width:67.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,835</P>
</TD><TD valign=top style='width:70.35pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>4,211</P>
</TD><TD valign=top style='width:78.15pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>( &nbsp;8.9%)</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style='width:140.4pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Net Income</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:67.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3,048</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:70.35pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3,453</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:78.15pt;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(11.7%)</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style='width:140.4pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Earnings Per Share</P>
</TD><TD valign=top style='width:67.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$ 0.939</P>
</TD><TD valign=top style='width:70.35pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$0.978</P>
</TD><TD valign=top style='width:78.15pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>( &nbsp;4.0%)</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style='width:140.4pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:67.5pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3,246</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:70.35pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3,532</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:78.15pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.15pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, First Half (six months ended June 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share): </P>
<TABLE style=border-collapse:collapse;width:509.4pt><TR><TD valign=top style=width:134.55pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2025</FONT></P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2024</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:134.55pt><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 19,663</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 21,740</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'>( &nbsp;9.6%)</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:134.55pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style='width:73.35pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>11,133</P>
</TD><TD valign=top style='width:72pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>13,018</P>
</TD><TD valign=top style='width:76.5pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(14.5%)</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style='width:134.55pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:73.35pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>6,349</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:72pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>7,321</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:76.5pt;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(13.3%)</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:134.55pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style='width:73.35pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>7,694</P>
</TD><TD valign=top style='width:72pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>9,010</P>
</TD><TD valign=top style='width:76.5pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(14.6%)</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style='width:134.55pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Net Income</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:73.35pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>6,089</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:72pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>7,409</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:76.5pt;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(17.8%)</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style='width:134.55pt;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Earnings Per Share</P>
</TD><TD valign=top style='width:73.35pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ 1.858</P>
</TD><TD valign=top style='width:72pt;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ 2.070</P>
</TD><TD valign=top style='width:76.5pt;border-bottom:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>(10.3%)</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style='width:134.55pt;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:73.35pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,278</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:72pt;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,579</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:76.5pt;border-top:0.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:76.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>BALANCE SHEET</P>
<TABLE style=border-collapse:collapse><TR style=height:21.6pt><TD valign=top style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>JUN 30, 2025</FONT></P>
</TD><TD valign=top style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>MAR 31, 2025</FONT></P>
</TD><TD valign=top style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>(audited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2024</FONT></P>
</TD><TD valign=top style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>JUN 30, 2024</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Cash &amp; Investments</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>$82,179</P>
</TD><TD valign=top style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>$83,325</P>
</TD><TD valign=top style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>$82,976</P>
</TD><TD valign=top style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$89,219</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>3,632</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>3,944</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>4,095</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>3,668</P>
</TD></TR>
<TR><TD valign=top style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Inventories</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>8,233</P>
</TD><TD valign=top style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>8,647</P>
</TD><TD valign=top style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>8,812</P>
</TD><TD valign=top style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>9,058</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Other Current Assets</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>331</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>483</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>448</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>377</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>94,375</P>
</TD><TD valign=top style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>96,399</P>
</TD><TD valign=top style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>96,331</P>
</TD><TD valign=top style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>102,322</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>10,257</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>9,945</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>9,762</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>10,194</P>
</TD></TR>
<TR><TD valign=top style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>16,170</FONT></P>
</TD><TD valign=top style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>16,175</FONT></P>
</TD><TD valign=top style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>16,445</FONT></P>
</TD><TD valign=top style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>17,516</FONT></P>
</TD></TR>
<TR style=height:21.15pt><TD valign=top bgcolor=#D3F0FE style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>$120,802</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>$122,519</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>$122,538</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$130,032</P>
</TD></TR>
<TR><TD valign=top style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>737</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>914</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>696</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>834</P>
</TD></TR>
<TR><TD valign=top style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>698</P>
</TD><TD valign=top style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>698</P>
</TD><TD valign=top style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>558</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1,517</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,712</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,363</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,547</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$2,254</P>
</TD><TD valign=top style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$4,324</P>
</TD><TD valign=top style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,757</P>
</TD><TD valign=top style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,939</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangible Assets</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>389</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>493</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>604</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>860</P>
</TD></TR>
<TR><TD valign=top style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'>Long Term Lease Liability </P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>256</P>
</TD><TD valign=top style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>269</P>
</TD><TD valign=top style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>282</P>
</TD><TD valign=top style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>275</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>698</P>
</TD></TR>
<TR><TD valign=top style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'>Deferred Revenue and Income Taxes</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>370</P>
</TD><TD valign=top style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>386</P>
</TD><TD valign=top style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>468</P>
</TD><TD valign=top style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>208</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>117,533</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>117,047</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>117,427</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>124,052</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:190.7pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>$120,802</P>
</TD><TD valign=top style=width:71.4pt><P align=right style='font:10pt Times New Roman;margin:0'>$122,519</P>
</TD><TD valign=top style=width:68.75pt><P align=right style='font:10pt Times New Roman;margin:0'>$122,538</P>
</TD><TD valign=top style=width:69.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$130,032</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20250724_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAAJHZFF]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20250724"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20250724.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20250724_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAAJHZFF]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20250724"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Securities Act File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20250724_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAAJHZFF]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20250724"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20250724.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20250724.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VAAJHZFF]. www.edgarsuite.com -->
<schema attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://utahmed.com/20250724' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:fil='http://utahmed.com/20250724' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:dei='http://xbrl.sec.gov/dei/2025'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250724_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250724_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250724_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2024-01-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2024-01-31'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='https://xbrl.sec.gov/dei/2025/dei-2025.xsd' namespace='http://xbrl.sec.gov/dei/2025'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 24, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Jul. 24,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20250724.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="utmd-20250724.htm">utmd-20250724.htm</File>
    <File>utmd-20250724.xsd</File>
    <File>utmd-20250724_def.xml</File>
    <File>utmd-20250724_lab.xml</File>
    <File>utmd-20250724_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20250724.htm": {
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20250724",
   "dts": {
    "inline": {
     "local": [
      "utmd-20250724.htm"
     ]
    },
    "schema": {
     "local": [
      "utmd-20250724.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20250724_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20250724_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20250724_pre.xml"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 34,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 19
   },
   "report": {
    "R1": {
     "role": "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D250724",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250724.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250724",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250724.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiscal Year End",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period End date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Form",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current with reporting",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Identification Number (TIN)",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Exchange",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://utahmed.com/20250724/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001096906-25-001180-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-25-001180-xbrl.zip
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M95F["YV$9T0H2N3L*BOPKU2$2?S<BG0(9?0_K2=!O>?6HT-(\L]*,2D^:?'
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MV &!"L$ $"MI$%?*Q");/THDI6[^W%"Q/71_XD6?.H7L20M7QAVE#54R)U0
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M3?KC?#MO,'_,/Y.<;_\+4$L#!!0    ( 'MP^%K'"W]X:3P  $_H 0 /
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M.^PZ:-@R-)2<O (,5G(?CY-G\?X2FF1W\@T<(O(_AR$^*LUM.9W\$"BR#:<
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MD#$A&UN2,0'NHGK&1/W,"/M[S8R8$[/N7V:$I1J=E4?,^W"H^H.,/!F6B<B
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MY.-I&H%9XR1_I.Z'@9([5<?6/,PA\3S\&3'7$ZR>Z,I30^_W*3_Q5/AU3EY
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M:/:]PO'TW%J Z>5EU!C=Y%W"Q"((:;9D]^U#AF-^?_U1OFT7WZ9[HN=@$7>
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M#9A'!1JIICCT/@U R::)/R)(UB1"F4T(MO8(@\:2XO(U*C8?/KNC!.O01][
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MX"2PB?_$IZCOQOX Z(XF(2]+6&X#,7V('9&3@EALI(0@[(1>3N?*3>$G$^B
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MLFW9M-S)<JHZ2J=7\5A-:,%VZ;$58XF2%NGA0K/V%:TK-$?72COU/W1FY>W
M11VJ?%WL<G*OTHM.> &.31R%-2IKLIQ,4]%[BT_%E])6TK"M$&>9#<M)EM2M
MV?V[U;R4H^H_-&XW7FKF0L_]<57+2_>W[ZJ6E^K?A:M*H4:]'^JS!PXKJQ6U
MIZZJ=@'$17]2A:I]]7D;&Z4<JU5[&=FB"Z6*8#^T?R?.,ZT'= V31@43]L=[
M-M2" T95A_;([6Y G7F=I'UTW5BLZ8?R[MYUBVHG^3H@AZ(:T>+I^>Z=.5:
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M4$L! A0#%     @ >W#X6FOIX&NU#@  K&0  !$              ( !
M '5T;60M,C R-3 W,C0N:'1M4$L! A0#%     @ >W#X6N:23=O+ @  ] @
M !$              ( !Y X  '5T;60M,C R-3 W,C0N>'-D4$L! A0#%
M  @ >W#X6B^+OL88 @  )@<  !4              ( !WA$  '5T;60M,C R
M-3 W,C1?9&5F+GAM;%!+ 0(4 Q0    ( 'MP^%K:A@$"'P@  -I.   5
M          "  2D4  !U=&UD+3(P,C4P-S(T7VQA8BYX;6Q02P$"% ,4
M" ![</A:1:)WW:@%  !&-   %0              @ %['   =71M9"TR,#(U
M,#<R-%]P<F4N>&UL4$L! A0#%     @ >W#X6L<+?WAI/   3^@!  \
M         ( !5B(  '5T;61?97@Y.7HQ+FAT;5!+!08     !@ & (0!  #L
%7@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>utmd-20250724_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20250724.xsd" xlink:type="simple"/>
    <context id="D250724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2025-07-24</startDate>
            <endDate>2025-07-24</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D250724" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D250724" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D250724" id="ixv-356">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D250724" id="ixv-357">2025-07-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D250724" id="ixv-358">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D250724" id="ixv-359">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D250724" id="ixv-360">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D250724" id="ixv-361">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D250724" id="ixv-362">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D250724" id="ixv-363">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D250724" id="ixv-364">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D250724" id="ixv-365">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D250724" id="ixv-366">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D250724" id="ixv-367">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D250724" id="ixv-368">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D250724" id="ixv-369">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D250724" id="ixv-370">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D250724" id="ixv-371">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D250724" id="ixv-372">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
